Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSammut, Stephen John
dc.contributor.authorGalson, Jacob
dc.contributor.authorMinter, Ralph
dc.contributor.authorSun, Bo
dc.contributor.authorchin, suet-feung
dc.contributor.authorDe Mattos-Arruda, Leticia
dc.contributor.authorSeoane, Joan
dc.date.accessioned2024-05-08T07:04:32Z
dc.date.available2024-05-08T07:04:32Z
dc.date.issued2024-05
dc.identifier.citationSammut SJ, Galson JD, Minter R, Sun B, Chin SF, De Mattos-Arruda L, et al. Predictability of B cell clonal persistence and immunosurveillance in breast cancer. Nat Immunol. 2024 May;25(5):916–24.
dc.identifier.issn1529-2916
dc.identifier.urihttps://hdl.handle.net/11351/11431
dc.descriptionB cell; Immunosurveillance; Breast cancer
dc.description.abstractB cells and T cells are important components of the adaptive immune system and mediate anticancer immunity. The T cell landscape in cancer is well characterized, but the contribution of B cells to anticancer immunosurveillance is less well explored. Here we show an integrative analysis of the B cell and T cell receptor repertoire from individuals with metastatic breast cancer and individuals with early breast cancer during neoadjuvant therapy. Using immune receptor, RNA and whole-exome sequencing, we show that both B cell and T cell responses seem to coevolve with the metastatic cancer genomes and mirror tumor mutational and neoantigen architecture. B cell clones associated with metastatic immunosurveillance and temporal persistence were more expanded and distinct from site-specific clones. B cell clonal immunosurveillance and temporal persistence are predictable from the clonal structure, with higher-centrality B cell antigen receptors more likely to be detected across multiple metastases or across time. This predictability was generalizable across other immune-mediated disorders. This work lays a foundation for prioritizing antibody sequences for therapeutic targeting in cancer.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNature Immunology;25(5)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCèl·lules B
dc.subjectMama - Càncer
dc.subjectImmunitat cel·lular
dc.subject.meshBreast Neoplasms
dc.subject.meshImmunologic Surveillance
dc.subject.meshB-Lymphocytes
dc.titlePredictability of B cell clonal persistence and immunosurveillance in breast cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41590-024-01821-0
dc.subject.decsneoplasias de la mama
dc.subject.decsvigilancia inmunológica
dc.subject.decslinfocitos B
dc.relation.publishversionhttps://doi.org/10.1038/s41590-024-01821-0
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sammut SJ] Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. The Royal Marsden Hospital NHS Foundation Trust, London, UK. [Galson JD, Minter R] Alchemab Therapeutics, Whittlesford, UK. [Sun BO] Wellcome Centre for Human Genetics, Oxford, UK. Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK. [Chin SF] Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. [De Mattos-Arruda L] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. [Seoane J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain
dc.identifier.pmid38698238
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record